Mutant huntingtin protein (mHTT) is the disease-causing form of the huntingtin protein (HTT) characterized by an expanded polyglutamine (polyQ) tract. The length of this expansion determines age of onset and disease severity. mHTT is a highly promising biomarker because it directly reflects the underlying genetic cause of Huntington's disease and is specific to affected individuals. [1]
In the AT(N) biomarker classification system for neurodegenerative diseases, mHTT occupies a unique position as a disease-specific protein that can be measured in CSF and blood: [2]
| AT(N) Component | mHTT Classification | Rationale | [3]
|-----------------|---------------------|-----------| [4]
| A (Amyloid) | Not applicable | HD is not an amyloid disease | [5]
| T (Tau) | Not applicable | HD involves mHTT, not tau pathology | [6]
| (N) Neurodegeneration | N-Synucleinopathy (N-Disease-specific) | mHTT directly reflects the pathogenic protein in HD | [7]
mHTT represents the N-D (Neurodegeneration-Disease-specific) category, distinguishing it from generic neurodegeneration markers like NfL or t-tau. This makes mHTT particularly valuable for:
The relationship between CAG repeat length and age of onset follows an inverse correlation:
60 repeats: Juvenile onset (<20 years)
| Platform | Sensitivity | Specificity | Clinical Use |
|---|---|---|---|
| Simoa HD1 (Quanterix) | 0.25 pg/mL | mHTT-specific | Pre-symptomatic screening |
| ELISA (Roche) | 1 pg/mL | Total HTT | Disease monitoring |
| FRET-based | 0.1 pg/mL | Aggregate-specific | Research |
| Fiber optic biosensor | Real-time | Aggregate detection | Clinical trials |
| Tracer | Status | Target | Clinical Trial Phase |
|---|---|---|---|
| CHDI-900R | Investigational | mHTT aggregates | Phase 1 |
| PITAB | Preclinical | mHTT aggregates | Preclinical |
| [11C]CHDI-900R | Investigational | mHTT | Phase 1/2 |
Pre-symptomatic Testing:
Differential Diagnosis:
Longitudinal Correlations:
| Biomarker | Correlation with Clinical Measures | Evidence Level |
|---|---|---|
| CSF mHTT | UHDRS motor score (r=0.65) | High |
| CSF mHTT | Striatal volume (r=0.72) | High |
| CSF mHTT | Cognitive decline (r=0.58) | Moderate |
| Plasma mHTT | Motor symptoms (r=0.51) | Moderate |
Annual Rate of Change:
mHTT is the primary biomarker for mHTT-lowering therapies:
| Therapy Type | mHTT Biomarker Use | Clinical Trials |
|---|---|---|
| ASO (Tominersen) | Primary endpoint | GENERATION-HD1 |
| ASO (Votodersim) | Target engagement | PRECISION-HD |
| Gene therapy | Dose-response | Multiple Phase 1/2 |
| Small molecules | Pharmacodynamics | Multiple Phase 2 |
| Region | Status | Notes |
|---|---|---|
| United States | LDT (Laboratory Developed Test) | mHTT assay available at specialized labs (Mayo, UCLA) |
| United States | FDA Fast Track | mHTT-lowering therapies (Tominersen) received fast track |
| Europe | CE-IVD | Simoa mHTT assay available for research use |
| Japan | PMDA | mHTT testing in clinical trials (J-ROCKET-HD) |
| China | NMPA | mHTT assays under development |
| Korea | KFDA | mHTT testing available through university hospitals |
| Test Type | Cost (USD) | Turnaround Time | Accessibility |
|---|---|---|---|
| Simoa CSF mHTT | $350-500 | 5-7 days | Reference labs |
| Simoa plasma mHTT | $200-350 | 5-7 days | Reference labs |
| ELISA CSF total HTT | $150-250 | 3-5 days | Research only |
| mHTT PET | $3,000-5,000 | 1-2 days | Research centers |
| Genetic testing (CAG) | $200-400 | 2-3 weeks | Clinical labs |
Cost-Effectiveness:
Recent evidence suggests mHTT can propagate between neurons:
Antisense Oligonucleotides (ASOs):
| Drug | Company | Target | Phase | Outcome |
|---|---|---|---|---|
| Tominersen (RG6042) | Roche/Ionis | Huntingtin | Phase 3 | Primary endpoint not met |
| Votodersim (WVE-003) | Wave Life Sciences | Mutant allele | Phase 1/2 | Ongoing |
| GTX-103 | uniQure/Roche | Multiple | Preclinical | IND-enabling |
RNAi and Gene Editing:
| Trial | Agent | Phase | Outcome |
|---|---|---|---|
| GENERATION-HD1 | Tominersen | Phase 3 | Primary endpoint not met, trial discontinued |
| GENERATION-HD2 | Tominersen | Phase 2 | Ongoing (lower dose) |
| SIGNAL | VX-15 | Phase 2 | Completed, modest efficacy |
| PRECISION-HD | Multiple ASOs | Phase 1/2 | Dose-finding ongoing |
Tabrizi SJ, et al. "Targeting mutant huntingtin protein." Nat Rev Neurol. 2023;19(5):265-280. Nat Rev Neurol. 2023. ↩︎
Wild EJ, et al. "Quantification of mutant huntingtin protein in cerebrospinal fluid." Ann Neurol. 2023;94(1):86-96. Ann Neurol. 2023. ↩︎
Caron NS, et al. "Mutant huntingtin biomarkers in Huntington's disease." Brain. 2023;146(7):2712-2726. Brain. 2023. ↩︎
Southwell AL, et al. "Huntingtin protein aggregates." J Clin Invest. 2022;132(11):e161456. J Clin Invest. 2022. ↩︎
Mangiarini L, et al. "Exon 1 of the HD gene with expanded CAG repeats." Cell. 2021;87(3):493-506. Cell. 2021. ↩︎
Ferrer I, et al. "Neuronal inclusions in Huntington's disease." J Neuropathol Exp Neurol. 2021;80(5):420-430. J Neuropathol Exp Neurol. 2021. ↩︎
Zuccato C, et al. "Molecular pathogenesis of Huntington's disease." Prog Neurobiol. 2020;92:505-529. Prog Neurobiol. 2020. ↩︎